Live News EQUITY ARTICLE M impact Sep 21, 2026, 04:47 AM UTC

HBM Healthcare Investments announces IPO of portfolio company Electra Therapeutics

HBM Healthcare Investments AG announced the successful initial public offering of its portfolio company Electra Therapeutics, which priced its upsized IPO at USD 15.00 per share, raising gross proceeds of approximately USD 350 million.

HBMN.S

SquawkNews Newsroom 1 updates Updated Sep 21, 2026, 04:47 AM UTC

Story updates

04:47:55 AM UTC

SquawkNews

HBM Healthcare Investments reported portfolio company Electra Therapeutics began trading on Nasdaq as ETRA on Sept. 18, 2026. Electra priced an upsized IPO at USD 15 per share, issuing 23,330,000 new shares for about USD 350 million gross proceeds. HBM invested USD 15 million in Electra’s 2025 Series C financing, then added USD 15 million in the IPO for USD 30 million total. Post-IPO stake stands at about 3.9%, valued at USD 32.8 million based on the first-day closing price. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Healthcare Investments AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2401904_en) on September 21, 2026, and is solely responsible for the information contained therein. (C)

2026 / 06:45 CET/CEST ══════════════════════════════════════════════════════════════════════════ Shares of Electra Therapeutics (Nasdaq: ETRA) began trading on 18 September 2026; HBM invested USD 15 million in the company's Series C financing in 2025 and a further USD 15 million as part of the IPO HBM Healthcare Investments today announced the successful initial public offering of its portfolio company Electra Therapeutics (NASDAQ: ETRA), a late clinical-stage biopharmaceutical company developing a novel class of precision medicines for immune-mediated diseases and cancer. 33 million new shares of common stock and raising gross proceeds of approximately USD 350 million.

HBM Healthcare Investments first backed Electra Therapeutics in October 2025, investing USD 15 million in the company's USD 183 million Series C financing, and invested a further USD 15 million as part of the IPO, bringing its total investment to USD 30 million. 9% of the company. 8 million. Electra's pipeline is focused on antibodies targeting signal regulatory proteins (SIRP).

Its lead product candidate, ipsoprubart, is being evaluated in a global registrational Phase 2/3 trial for secondary hemophagocytic lymphohistiocytosis (sHLH), a rare and life-threatening hyperinflammatory disorder. S. FDA and Priority Medicines (PRIME) designation from the European Medicines Agency. com.

2026 CET/CEST References Visible links 1. com 2.